BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Vimal Mehta Sells 5,268 Shares

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Vimal Mehta sold 5,268 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $2.62, for a total value of $13,802.16. Following the transaction, the chief executive officer now directly owns 43,564 shares of the company’s stock, valued at approximately $114,137.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

BioXcel Therapeutics Price Performance

BioXcel Therapeutics stock traded down $0.03 during mid-day trading on Monday, hitting $2.63. The company’s stock had a trading volume of 160,505 shares, compared to its average volume of 1,467,548. The firm’s 50 day moving average is $3.02 and its 200 day moving average is $3.18. The company has a market cap of $80.43 million, a PE ratio of -0.43 and a beta of 0.40. BioXcel Therapeutics, Inc. has a 52-week low of $1.91 and a 52-week high of $29.56.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.22. The firm had revenue of $0.38 million during the quarter, compared to the consensus estimate of $1.17 million. BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. As a group, analysts forecast that BioXcel Therapeutics, Inc. will post -2.28 EPS for the current year.

Institutional Investors Weigh In On BioXcel Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp raised its stake in shares of BioXcel Therapeutics by 17.7% during the 2nd quarter. State Street Corp now owns 2,072,199 shares of the company’s stock worth $13,801,000 after purchasing an additional 311,516 shares in the last quarter. BlackRock Inc. raised its stake in shares of BioXcel Therapeutics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 1,463,372 shares of the company’s stock worth $17,297,000 after purchasing an additional 40,025 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of BioXcel Therapeutics during the 1st quarter worth about $24,904,000. Vanguard Group Inc. raised its stake in shares of BioXcel Therapeutics by 8.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,220,530 shares of the company’s stock worth $3,088,000 after purchasing an additional 91,808 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of BioXcel Therapeutics by 91.3% during the 3rd quarter. Ameriprise Financial Inc. now owns 668,370 shares of the company’s stock worth $1,691,000 after purchasing an additional 318,910 shares in the last quarter. 30.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Bank of America decreased their target price on BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Canaccord Genuity Group decreased their target price on BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. UBS Group reaffirmed a “neutral” rating and set a $4.00 target price (down from $9.00) on shares of BioXcel Therapeutics in a report on Wednesday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of BioXcel Therapeutics in a report on Monday, March 18th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, BioXcel Therapeutics has a consensus rating of “Hold” and an average price target of $16.86.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.